{"name":"DH Bio Co., Ltd.","slug":"dh-bio-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Haporine-S","genericName":"Haporine-S","slug":"haporine-s","indication":"Metastatic triple-negative breast cancer","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Restasis (cyclosporine 0.05%)","genericName":"Restasis (cyclosporine 0.05%)","slug":"restasis-cyclosporine-0-05","indication":"Treatment of chronic dry eye syndrome","status":"phase_3"}]}],"pipeline":[{"name":"Haporine-S","genericName":"Haporine-S","slug":"haporine-s","phase":"phase_3","mechanism":"Haporine-S is a small molecule that targets the PI3K/AKT/mTOR pathway.","indications":["Metastatic triple-negative breast cancer","Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Restasis (cyclosporine 0.05%)","genericName":"Restasis (cyclosporine 0.05%)","slug":"restasis-cyclosporine-0-05","phase":"phase_3","mechanism":"Restasis works by increasing tear production in patients with dry eye syndrome.","indications":["Treatment of chronic dry eye syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}